Showing results (111-120 of 141) with videos related to
Sort By:
Pageof 15
Igie : Innovation, Investigation and Insights|July 3, 2026
Artificial intelligence detection of endoscopic moderate-to-severe ulcerative colitis: a novel tool to enhance clinical trial recruitmentLaurie B Grossberg, Grace Geeganage, Aditya Mithal, et al.Journal of Clinical Medicine|September 5, 2020
Clinical Impact of Corrections to Infliximab and Adalimumab Monitoring Results with the Homogeneous Mobility Shift AssayKonstantinos Papamichael, Valerio J Thomas, Andrea Banty, et al.European Journal of Gastroenterology & Hepatology|March 23, 2026
Lower drug clearance of adalimumab is associated with proactive therapeutic drug monitoring and mucosal healing in patients with inflammatory bowel diseaseTina Deyhim, Alessandra Saraga, Ajay Gade, et al.Inflammatory Bowel Diseases|July 2, 2026
Higher body mass index is associated with lower drug concentrations in patients with inflammatory bowel disease treated with ustekinumab but not vedolizumabJoyce Lee, Rachel Porth, Alessandra Saraga, et al.Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|March 10, 2020
Comparison of Assays for Therapeutic Monitoring of Infliximab and Adalimumab in Patients With Inflammatory Bowel DiseasesKonstantinos Papamichael, William T Clarke, Niels Vande Casteele, et al.European Journal of Gastroenterology & Hepatology|February 9, 2010
A pilot study comparing hydrocortisone premedication to concomitant azathioprine treatment in preventing loss of response to infliximabGerassimos J Mantzaris, Nikolaos Viazis, Kalliopi Petraki, et al.Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|January 9, 2021
Patients With Low Drug Levels or Antibodies to a Prior Anti-Tumor Necrosis Factor Are More Likely to Develop Antibodies to a Subsequent Anti-Tumor Necrosis FactorNiels Vande Casteele, Maria T Abreu, Sarah Flier, et al.Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|November 20, 2013
Dose optimization is effective in ulcerative colitis patients losing response to infliximab: a collaborative multicentre retrospective studyMonica Cesarini, Konstantinos Katsanos, Konstantinos Papamichael, et al.Journal of Clinical Medicine|January 28, 2026
Higher Anti-Drug Antibody Levels to Anti-Tumor Necrosis Factor Therapies Are Associated with Treatment Failure in Patients with Inflammatory Bowel DiseaseAlessandra Saraga, Tina Deyhim, Ajay Gade, et al.Digestive Diseases and Sciences|November 18, 2017
Targeted Physician Education and Standardizing Documentation Improves Documented Reporting with Inflammatory Bowel Disease Quality Measures in a Large Academic and Private PracticeJoseph D Feuerstein, Konstantinos Papamichael, Sara Popejoy, et al.Pageof 15